Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Management of symptomatic hyponatremia (e.g., severe hyponatremia with neurological symptoms),Reduction of intracranial pressure in cerebral edema (off-label, but commonly used),Hypovolemia and hyponatremia due to salt depletion (off-label use)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable: sodium and chloride are endogenous electrolytes; administered dose mixes with body pools and is eliminated via renal excretion with a half-life dependent on renal function and hydration status. In euvolemic individuals with normal renal function, the terminal elimination half-life of excess sodium is approximately 6–12 hours.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Sodium chloride is not metabolized; it is distributed in extracellular fluid and excreted primarily by the kidneys. No hepatic metabolism.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal (essentially 100%): sodium and chloride ions are excreted unchanged in urine. No biliary or fecal elimination of intact drug; sodium and chloride are obligately filtered and variably reabsorbed based on volume status and renal function.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
0%: sodium and chloride ions are not protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Total body water (0.6 L/kg): sodium distributes primarily in extracellular fluid (0.2 L/kg); chloride distributes similarly. Clinical meaning: reflects rapid equilibration with the extracellular space.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% (bioequivalent to endogenous electrolytes). No oral or other relevant routes for hypertonic saline; oral administration would have variable absorption and is not used.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific dose adjustment for renal impairment based on GFR. Use with caution in patients with renal failure due to risk of fluid overload and hypernatremia. Monitor renal function and fluid balance closely.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific dose adjustment for hepatic impairment based on Child-Pugh score. Use with caution in patients with cirrhosis due to risk of ascites and fluid overload. Monitor serum sodium and fluid status.
No dosage adjustment required for hepatic impairment.
Intravenous 3% sodium chloride: 0.5-1 m L/kg over 30-60 minutes, with a maximum rate of 1 m L/kg/hour, titrated to serum sodium. Typical dose for severe hyponatremia: 1-2 m L/kg/hour. Monitor serum sodium every 1-2 hours.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Lower initial infusion rates (e.g., 25-50 m L/hour) due to decreased renal function and higher risk of fluid overload. More frequent monitoring of serum sodium and hemodynamic status. Avoid rapid correction (>8 m Eq/L per 24 hours).
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of osmotic demyelination syndrome (central pontine myelinolysis) if serum sodium is corrected too rapidly; use with caution in patients with heart failure, renal impairment, or pre-existing hypernatremia; monitor serum sodium, chloride, and fluid status; avoid extravasation as it may cause tissue necrosis.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypernatremia; fluid overload; severe renal impairment with oliguria or anuria; pre-existing hyperchloremia; concurrent use of medications that cause sodium retention (e.g., corticosteroids) should be considered relative contraindication; not for use as a maintenance fluid.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No direct food interactions. However, dietary sodium restriction is typically indicated in hyponatremia management, but not during active treatment with 3% saline.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correction of hyponatremia can cause osmotic demyelination syndrome, which may affect both mother and fetus. First trimester: no known teratogenic risk. Second and third trimesters: cautious use indicated as maternal fluid and electrolyte imbalances can impact fetal homeostasis.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Sodium chloride is a normal constituent of breast milk. Intravenous infusion of hypertonic saline may transiently increase maternal serum sodium, but negligible transfer into milk is expected. M/P ratio not established. Generally considered compatible with breastfeeding, but monitor infant for signs of electrolyte imbalance if maternal therapy is prolonged or high-dose.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy does not typically require dose adjustment of hypertonic saline. However, pregnancy-associated plasma volume expansion and altered renal function may influence sodium handling; monitor serum sodium levels frequently. Use with caution in preeclampsia due to increased risk of fluid overload.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Hypertonic saline (3%) is used for rapid correction of symptomatic hyponatremia (e.g., seizures, coma). Infuse via central line to avoid phlebitis; use an infusion pump. Monitor serum sodium every 2-4 hours; do not exceed 8-12 m Eq/L rise in 24 hours to prevent osmotic demyelination. Reserve for ICU setting.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is given intravenously to raise low sodium levels.,You will have frequent blood tests to monitor your sodium levels.,Report any new headache, confusion, or muscle weakness immediately.,Do not stop the infusion or adjust the rate on your own.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is a Electrolyte that works by Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is: Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correc. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.